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Abstract
Megalencephaly and macrocephaly present with a head circumference measurement 2 standard deviations above the age-related
mean. However, even if pathologic events resulting in both megalencephaly and macrocephaly may coexist, a distinction between
these two entities is appropriate, as they represent clinical expression of different disorders with a different approach in clinical work-
up, overall prognosis, and treatment. Megalencephaly deﬁnes an increased growth of cerebral structures related to dysfunctional
anomalies during the various steps of brain development in the neuronal proliferation and/or migration phases or as a consequence of
postnatal abnormal events. The disorders associated with megalencephaly are classically deﬁned into 3 groups: idiopathic or benign,
metabolic, and anatomic. In this article, we seek to underline the clinical aspect of megalencephaly, emphasizing the main disorders
that manifest with this anomaly in an attempt to properly categorize these disorders within the megalencephaly group.
Abbreviations: BRRS = Bannayan–Riley–Ruvalcaba syndrome, CLOVE = Congenital lipomatous overgrowth, vascular
malformations, and epidermal nevi, GCPS = Greig cephalo-polysyndactyly syndrome, HEXA = b-hexosaminidase A, HEXB =
b-hexosaminidase B, MCAP = Megalencephaly-capillary malformation, MLC = Megalencephalic leukoencephalopathy, MPPH =
Megalencephaly-polymicrogyria-polydactily-hydrocephalus, MPS = Mucopolisaccharidoses, MRI = Magnetic Resonance Imaging,
NAA = N-acetylaspartatic acid, PMSE = Polyhydramnios, megalencephaly, and symptomatic epilepsy syndrome, SDs = Standard
Deviations, SGBS = Simpson–Golabi–Behmal syndrome, TSD = Tay-Sachs disease.
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1. Introduction the measurement must be checked with the head circumferenceMeasuring the head circumference is an essential component of
the physical examination in pediatric practice and in particular
in neuropediatric assessment. The measurement of the head
circumference is a challenge for pediatricians, as it is not easy to
carry out in young children. In some cases, a correct reading of
the headmeasurement may be particularly unfeasible, as the child
may be too much restless or the tape measure may be not placed
properly and the patient’s hair may be too thick to give a correct
result. A proper measure of the head circumference should be
performed by putting the tape measure along the most prominent
diameter of the occiput and the mid forehead; then, the results ofEditor: Vasile Valeriu Lupu.
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1growth charts, according to the age, gender, and height
parameters.[1] Correlation with the maternal and paternal head
circumference is useful. The newborn brain is reported to weigh
about 370g and increases about 4-fold from infancy to childhood
till reaching an adult’s weight of about 1500g.[2]2. Distinguishing between megalencephaly and
macrocephaly
By deﬁnition, both in megalencephaly and macrocephaly, the
measurement of head circumference is reported to be 2 standard
deviations (SDs) above the age-related mean. Distinction between
these two abnormally large head circumferences is useful because
they represent clinical expression of different disorders with
different approaches in clinical work-up, overall prognosis, and
treatment.[3,4] Sometimes, this distinction is not performed, and
the terms are not appropriately referred in scientiﬁc papers but
instead are used interchangeably. Megalencephaly deﬁnes an
increased growth of cerebral structures related to dysfunctional
anomalies during the various steps of brain development in the
neuronal proliferation and/or migration phases or as a conse-
quence of postnatal abnormal events that cause excessive cerebral
growth. In contrast, in macrocephaly, the increased head
circumference is linked to various events that can result in an
increase of orbito-frontal head circumference for age, including
anomalies of bone skull structures, subdural ﬂuid collections,
hydrocephalus, intracranial masses, and arteriovenous malfor-
mations.
However, sometimes, adverse events resulting in both
megalencephaly and macrocephaly may coexist in the same
individual.
Megalencephaly is maintained to be prognostically more
severe than macrocephaly and has been reported more frequently
Figure 1. Diagnostic ﬂowchart for increased head circumference in children.
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resistant epilepsy.
In a clinical scenario, distinction between megalencephaly and
macrocephaly is useful. In this article, we seek to underline the
clinical aspects of megalencephaly, emphasizing the main
disorders that manifest with this anomaly, in an attempt to
properly distinguish these disorders within the category of
megalencephaly.3. Megalencephaly classiﬁcation
Fletcher [5] is credited to have introduced the term megalence-
phaly while reporting a patient with this anomaly. The same
author and successively Wilson [6] backed up that this term
should be limited to patients with cerebral overgrowth in
association with neurological dysfunction.[7] Megalencephaly
may involve all the encephalon or only a localized portion. Ono
et al[8] reported 3 neurologically normal adolescents who showed
enlargement of the right frontal lobe with increased volume
of subcortical and deep white matter and thickening of the
ipsilateral genu of the corpus callosum. At present, megalence-
phaly is indicated by an oversized and overweight brain, aside
from any neurological dysfunction. Megalencephaly is classically
deﬁned into 3 groups, according to the etiology: idiopathic or
benign, metabolic, and anatomic (Fig. 1).
Benign or idiopathic megalencephaly refers to children who
have an abnormally large head with no neurological impairment.2An increased head circumference is often reported in one or both
the parents. In these individuals, the head circumference
gradually increases from infancy to become stable at around
18 months of age or more with normal cerebral development.[4]4. Metabolic megalencephaly
Some inborn errors of metabolism may manifest with mega-
lencephaly. Diagnosis of this disorder is based on speciﬁc
neurological features associated with the megalencephaly.
Familial history of similar disorders with a recessive hereditary
pattern, either autosomal or sex-linked, or a history of marriages
among relatives may be suggestive for a metabolic disorder. The
clinical course is clearly progressive with a more or less rapid
neurological impairment, which may also involve other organs,
including the eyes, heart, spleen and liver, skin, and muscles. In
these patients, increased intracranial pressure may also be
present.
Physical examination in pediatric patients with megalence-
phaly and metabolic disorders show signs of neurological
impairment, such as large or tense fontanels, enlarged sutures,
the sun-setting sign, hypotonia, irritability, or, in older children,
neurodevelopment delay, lethargy, and/or seizures. In these
patients, the physical examination should be extended to the
other organs; hepatosplenomegaly and/or other anomalous
manifestations may indicate the diagnosis of neurometabolic
disease. Laboratory ﬁndings are mandatory for a diagnosis of
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defect, which can be observed in serum, urine, cerebrospinal ﬂuid,
and tissue culture. Some of these patients may die before the head
circumference ever reaches the maximum level.
Three groups of metabolic disorders have been suggested to be
associated with megalencephaly: defects of the organic acids,
metabolic leukoencephalopathies or “metabolic encephalopa-
thies”, and lysosomal storage diseases.[4,9]4.1. Defects of organic acids
Defects of organic acids include glutaric aciduria type 1 (gene
defect GCDH) and L–2-hydroxyglutaric aciduria (gene defect
L2HG). Glutaric aciduria type 1 is caused by deﬁciency of
glutaryl-CoA dehydrogenase involved in the pathway of lysine to
hydroxylysine and L-tryptophan. Abnormal head circumference
is present since birth and is the earliest andmost distinctive sign of
this disorder. The enzymatic defect causes an accumulation of
glutaric acid and 3-hydroxyglutaric acid that interferes in the
energetic metabolism and oxidative stress, provoking neuronal
impairment.[10] Untreated patients present with dystonic move-
ment disorders in infancy. Brain MRI presents with widening of
Sylvian ﬁssure (batwing appearance), diffuse white matter signal
abnormalities, and bilateral high signal in the basal ganglia.
Fronto-temporal atrophy has also been reported.[11] The
pathological features are characterized by striatal injury conse-
quent to encephalopathic crises associated with frequent
infectious episodes.[12]
L-2-hydroxyglutaric aciduria includes a group of neuro-
metabolic disorders in which the metabolic defect causes an
elevated elimination of hydroxyglutaric acid in the urine. L-2-
hydroxyglutaric aciduria is the most common and severe form
that manifests with neurological impairment, large head,
cerebellar sign, and epileptic seizures.[13] The MRI images
reported by Steenweg et al [14] displayed a cerebral white matter
involvement that mainly affected the frontal and subcortical
regions. The abnormal subcortical white matter anomalies show
a mildly swollen appearance with an initial aspect partially
multifocal. Neuropathologic examination shows mild cortical
neuronal loss with intense gliosis, spongiosis, and vacualitation
of the neuronal cells. Subcortical white matter contains numerous
hyperplastic astrocytes with severe demyelinization and cystic
cavities.[15]
D-2-hydroxyglutaric aciduria is caused by recessive mutation
inD2HGDH (type 1) or by dominant gain-of-functionmutations
in IDH2 (Type 2). In this form, the megalencephaly is often
present and is associated with cardiomyopathy, hypotonia, and
intellectual delay. Brain MRI shows conﬂuent subcortical white
matter lesions that spread centrifugally with atrophy of the
cerebellar vermis and involvement of dentate nuclei.[16]4.2. Metabolic encephalopathies
Canavan disease is caused by deﬁciency of aspartoacylase that
leads to the accumulation of N-acetylaspartic acid (NAA) in the
brain and in white matter. In this disorder, there is a degeneration
of myelin in the phospholipid layer that isolates the axon. The
NAA in a high concentration results in myelin vacuolization and
astrocyte swelling. The clinical features in the infantile form are
characterized by a rapidly increasing head circumference, severe
hypotonia, and irritability with an onset at around 3 to 6 months
of age. Subsequently, feeding difﬁculties with poor growth
becomemore evident as the delayedmilestones. Hypertonia, joint3stiffness, and seizures develop rapidly, and most of the patients
die in the ﬁrst decade of life. MRI reveals diffuse white matter
degeneration mainly involving cerebral hemispheres with exten-
sive thickening of the white matter. Diagnosis is made in the
presence of high levels of urinary NAA.[17] Pathologic studies
show spongy degeneration of white matter with no speciﬁc
morphologic changes.
Alexander disease has been the ﬁrst identiﬁed primary genetic
disorder of astrocytes and is caused by mutations in the gene
encoding glial ﬁbrillary acidic protein (GFAP). Progressive
neurological impairment, megalencephaly, and a typical MRI
pattern are classically recognized as diagnostic. The brain MRI
shows characteristic symmetric and extensive abnormalities with
frontal predominance and relative sparing of occipital and
temporal white matter.[18]
Van der Knaap et al,[19] in a report concerning the brain MRI
of patients with Alexander disease, have identiﬁed 5 criteria, 4 of
which are remarkable, for the diagnosis of the disease: an
extensive cerebral white matter change with frontal predomi-
nance; a periventricular rim with high signal on T1-weighted
images and low signal on T2-weighted images; abnormalities of
basal ganglia and thalami; brain stem abnormalities; and contrast
enhancement of particular gray and white matter structures. The
pathological ﬁndings show a brain that is typically too large and
too heavy; extensive paucity of myelin is found in the hemispheres
in which frontal lobes are more affected than the others. The
presence of Rosenthal ﬁbers throughout the central nervous
system (CNS) is the pathological hallmark of the disorder. A
notable increase of astrocytes ﬁlled with Rosenthal ﬁbers is
reported to mainly affect the subpial, perivascular, and
subependymal pattern. Rosenthal ﬁbers are mainly found in
the outer, subpial layers of the cerebral cortex, in frontal white
matter, and near the periventricular area. [20,21]
Megalencephalic leukoencephalopathy (MLC) with subcorti-
cal cysts associated withMLC1 and HEPACAM gene mutations
and leukoencephalopathy with vanishing white matter, which is
linked to mutations in EIFB1, EIFB2, EIFB3, EIFB4, and EIFB5
(eukaryote translational initiation factor B1-B5) genes, have been
reported in patients presenting an abnormal head circumference.
In MLC, the large head may be present at birth, but more often it
appears during the ﬁrst year of life. The degree of abnormal head
circumference may reach 4 to 6 SDs above the average. After the
ﬁrst year, the head growth tends to normalize and to stabilize
within the 98th percentile. Patients present with hypotonia,
cognitive delay, and seizures.[22] The brain MRI shows diffusely
abnormal and mildly swollen white matter. Subcortical cysts are
almost invariably present in the anterior temporal region and
often in the frontal-parietal region. The subcortical cysts tend to
increase in size and number.[23]
In leukoencephalopathy with vanishing white matter, the
clinical signs begin to appear during early childhood with
spasticity and motor incoordination. The pathological ﬁndings
show a gray matter of normal structure, while the white matter
appears rareﬁed with a small number of axons and U-ﬁbers and
presence of small cavities in the white matter. The presence of
foamy oligodendrocytes is typical of this disorder. The brainMRI
displays reversal of signal intensity of the white matter. Recovery
sequences and holes in the white matter are found.[23,24]4.3. Lysosomal storage diseases
Lysosomal storage diseases are also associated with an
abnormally large brain. Tay–Sachs disease (TSD) is a disorder
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15q23–24. Two forms of b-hexosaminidase are recognized:
b-hexosaminidase A [HEXA] is a heterodimer comprised of an
a-acid and a b subunit, while b-hexosaminidase B [HEXB] is
formed by two b subunits. The clinical signs begin at the age of 6
months with a progressive delay of the developmental milestones
and hypotonia. A large head becomes apparent by 1 year of age
due to an abnormal content of the ganglioside GM2, which
accumulates in the brain. Short stature, progressive spasticity,
and seizures with visual degeneration and deafness are the
presenting clinical signs. Cherry red spots at the fundoscopic
examination are useful for diagnosis. Pathologic examination
displays massively increased weight and volume of the brain,
which may weigh more than twice than a normal brain. Cystic
degeneration of the cerebral white matter (status spongiosus) and
atrophy of the cerebellar hemispheres are frequently observed.[25]
Sandhoff disease is linked to an inherited deﬁciency of HEXA
and HEXB that are needed for the degradation of the neuronal
membrane components (ganglioside GM2, its derivate GA2, the
glycolipid globoside). TheHEXB gene is located on chromosome
5q13. As for TSD, signs begin at the age of 6 months with large
head, seizures, cherry red spots, and doll-like facies.[26] In the
brain, an amount of GM2 asialoganglioside that is 300 times
more than normal is found in affected patients.[25]
Large head circumference above the normal has been reported
in patients with other metabolic disorders, but they do not have
all the characteristics to be included in the group of mega-
lencephaly, for example, Mucopolisaccharidoses (MPS) type 1-
Hurler (gene mutation IDLIA), MPS II-Hunter syndrome
(IDS gene), and MPS III-Sanﬁlippo syndrome (SGSH, HAGLN,
HGSNAF, GNS genes). In these patients, the head circumference
is usually normal at birth, and it gradually increases in the
ﬁrst years of life (usually between 1 and 3 years). The increased
head circumference in Type I-Hurler and type II-Hunter is
linked to chronic communicating hydrocephalus, progressive
cerebral storage of glycosaminoglycans, enlarged cerebral
perivascular spaces, and neuroinﬂammation. In MPS III, the
increase of head circumference is noticed in the ﬁrst decade, but
there is a progressive decrease, and in adulthood, the head
circumference, due to progressive brain atrophy, returns to a
normal range.
Volumetric analysis of cortical gray matter, cortical white
matter, corpus callosum, and frontal lobes in MPS II, as reported
by Yund et al,[27] notes that the mean volumes are larger, but they
are not statistically signiﬁcant different than controls. In a large
study of 118 patients with MPS III by de Ruijter et al,[28] mean
head circumference SDs according to age was 0.88 for all patients
(boy 0.71, girl 1.1, P< .001). The data reported by Yund et al[27]
conﬁrmed our experience of several patients followed in the
metabolic center of the University of Catania.
Large head has been anecdotally described in patients with
Krabbe disease, but as reported by Barone et al [29] in 11 patients
with classic infantile and late-onset Krabbe disease, no patients
with an abnormally large head have been found.5. Anatomic megalencephaly
This group of disorders manifests with developmental mega-
lencephaly linked to a single gene mutation involving early brain
cellular growth, migration, or replication. Mutation in the
mammalia Target of Rapamyicin (mTOR), mitogen-activated
protein kinase, originally called “extracellular signal-regulated
kinases” (MAPK/ERK), and Sonic hedgehog (SHH) pathways4have been frequently reported as pathogenetic events causing
megalencephaly as a single anomaly or in association with other
body structural anomalies.[4]
5.1. Megalencephaly within dwarﬁsm
Achondroplasic patients have a mutation at the FGF3 gene,
codon 380. In these patients, the cranium is disproportionately
large relative to height, but it is unusual to reach level above 2
SDs. The patients present with a prominent forehead, the nasal
bridge is moderately ﬂat, and the chest is narrow. Most of these
signs may be present at birth. The cognitive aspect is normal, but
cerebral complication may be frequent.[30]
5.2. Megalencephaly within gigantism (more often
associated with ventricular megalencephaly)
Sotos syndrome (also known as cerebral gigantism) is a prenatal
and postnatal overgrowth syndrome linked to a mutation of the
gene encoding the nuclear receptor set domain containing
protease 1 (NSD1) on chromosome 5q35. Patients present with
tall stature, large head, distinctive craniofacial features, gait
dyspraxia, seizures, and developmental delay. Some of these
patients also present an auto- and hetero-aggressivity causing
severe damage. Height tends to normalize after puberty, whereas
the head circumference persists to be large.[31]
Brain neuroimaging shows abnormalities involving the cavum
septum pellucidum and cavum vergae, hypoplasia of corpus
callosum, enlarged subarachnoidal spaces, ventricle dilatation,
slight hypodensity of the white matter, and cerebral atrophy.[31]
Schaefer and Buehler [32] reported a neuroradiologic study
performed in 40 patients affected by Sotos syndrome.Most of the
anomalies were found in the ventricular system with ventricles
enlarged, and prominence of the trigone and occipital horns,
extracerebral supratentorial, and increased posterior fossa ﬂuid
spaces; gray matter heterotopias, periventricular leukomalacia,
periventricular leukomalacia, cavum septum pellucidum, and
corpus callosum anomalies were also reported.
Phenotypic overlap between Sotos and Weaver syndrome has
been widely reported. In Weaver syndrome, tall stature has been
reported as the most common feature observed in 90% and
intellectual disability in 80% of patients.[33] Additional clinical
features include camptodactyly, soft and doughy skin, umbilical
hernia, and a low hoarse cry.
Simpson–Golabi–Behmal syndrome (SGBS) types I and II show
clinical signs of multiple congenital abnormalities, including pre-
post natal overgrowth, distinctive craniofacial features, large
head, and organomegaly. Other anomalies may be observed
involving the skeletal system, heart, CNS, kidney, and gastroin-
testinal tract.[34] Genomic rearrangements and point mutations
involving the glycan-3 gene (GPC3) at Xq26 are the causal events
associated with SGBS. Large head has been reported in about
70% of children with SGBS. MRI shows midline defect, such as
abnormal corpus callosum, central lipomata, and hydrocepha-
lia.[34] Craniosynostosis may be frequently present.
Bannayan–Riley–Ruvalcaba syndrome (BRRS) is a well-known
disorder linked to a germline mutation of PTEN. This syndrome,
with its allelic disorders including the Cowden syndrome,
manifests with an overgrowth of connective tissue and multiple
benign hamartomatous lesions and megalencephaly. The Cowden
syndrome is associated with a high risk for thyroid, breast, and
endometrial cancers. Patients with BRRS present a large head,
intestinal polyposis, lipomas, and pigmented penile macules.[35]
Bhargava et al [36] reported a brain neuroradiologic study in
[43]
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matter cysts localized in the parietal lobe in all thepatients,whereas
cysts were also reported in the frontal lobe in 3 and in 1 in the
temporal lobe, respectively. The cysts were predominantly
surrounded by white matter t 2 hyperintensities. Both these
syndromes are enclosed in the spectrum of PTEN hamartoma
tumor syndromes linked to the germline mutations in the tumor
suppressor PTEN gene located in chromosome 10q23.3.[37]
5.3. Megalencephaly within syndromes
Recently, megalencephaly as a presenting sign has been reported in
two syndromes, which represent a typical example of anatomic
brain overgrowth: megalencephaly–polymicrogyria–polydactily–
hydrocephalus (MPPH) and megalencephaly-capillary malforma-
tion (MCAP). De novo germline mutations in APT3 and PIK3R2
have been reported in patients with MPPH. This syndrome is
characterized by abnormally increased head sizes, reaching levels
above 10 SDs. Ventriculomegaly that may progress to hydroceph-
alus, cerebelllar tonsillar ectopia, and polymicrogyria are other
associated anomalies. Cutaneous lesions are accompanying
features consisting of capillary malformations and variable
connective tissue dysplasia. Mild focal or segmental body
overgrowth, together with ﬁnger or toe syndactily and postaxial
polydactily may be present.[9] MCAP has many features over-
lapping theMPPH. It hasbeenalso linked to thePIK3CAgene.The
genes PIK3R2, ATK3, and PIK3CA are members of the
phosphatidyl inositol-3kinase of the AKT pathway and are
present in all the developmental brain cellular activities, including
apoptosis. MPPH shows many of the same features as the MCAP,
including the severe megalencephaly, with the exception of the
postaxial polydactyly, which is more common and more typical in
the MPPA syndrome.[38–40]
5.4. Pretzel syndrome
Polyhydramnios, megalencephaly, and symptomatic epilepsy
syndrome (PMSE), which is also called Pretzel syndrome, is
characterized by infantile-onset epilepsy, neurocognitive delay,
and craniofacial dysmorphism. PMSE is caused by homozygous
deletion of exons 9 to 13 of theLYK5/STRADA gene that encodes
the pseudokinase STRADA, an upstream inhibitor of mammalian
target of rapamycin complex 1.[41] Polyhydramnios is frequently
reported: around 80% of the cases reported present with this
anomaly. The psychomotor disturbances are very impressive with
cognitive delay, early seizures, and muscle involvement that are
hypotrophic. The affected child lies in a particular position termed
a“Pretzel-like posture.”Atrial septal defect is reported inone-third
of the patients. The large head commonly present in this child as
reported by brain MRI is linked to the presence of extracerebral
ﬂuid or hydrocephalus in association with excessive cerebral
growth. Histopathologic evidence of heterotopic neurons in
subcortical white matter and subependymal regions were reported
by Puffenberger et al [42] wherein a single postmortem neuropath-
ologic study showed megalencephaly, ventriculomegaly, cytome-
galy, and extensive vacuolization and astrocytosis of whitematter.
A constitutive activation of mTORC1 signaling pathway was
reported by the authors in the frontal cortex, basal ganglia,
hippocampus, and spinal cord.
5.5. Other syndromes
PTEN gene mutations have been observed in patients with
increased head circumference and autistic behavior. Butler et al5reported 18 individuals who presented a germline PTEN
mutation with X-linked intellectual disability, large head, and
neurobehavioral features of autistic spectrum disorder. In these
patients (13 males), the head circumerence increase ranged from
2.5 to 8.0 SDs. Large head and autism has been reported in
patients with RAB1q mutation.[9]
Congenital lipomatous overgrowth, vascular malformations,
and epidermal nevi (CLOVE) syndrome has been reported in
association with CNSmalformations and seizures.[44] Among the
patients reported by Gucev et al,[44] a newborn girl presented
with massive lymphatic truncal vascular malformation with
cutaneous venous anomaly and overgrown feet and splayed toes.
Cranial computed tomography (CT) showed encephalomalacia,
widening of ventricles and the sulci, and hemimegalencephaly.
Patients with CLOVE syndrome and megalencephaly have also
been reported,[44] but megalencephaly is not a prominent sign in
this syndrome.
Macrocephaly, alopecia, cutis laxa, and scoliosis is a rare
condition with an autosomal recessive inheritance. Mutations in
RIN2 (chromosome 20p11.23) have been linked to this
disorder.[45]RIN2 gene encodes the RAS and RAB interactor
protein 2, which is involved in cell trafﬁcking. The presenting
clinical features consist of progressive facial coarsening, gingival
hypertrophy, severe scoliosis, sparse hair, cutis laxa, and joint
hyperlaxity.[46]
PMSE [42] is linked to homozygous 7-kilobase deletion in
LYK5, which encodes STE20-related adaptor protein, a
pseudokinase functionally necessary for proper localization
and function of serine/threonine kinase 11 (a.k.a. LKB1). The
LYK5 deletion is associated with polyhydramionis, preterm
labor, and distinctive craniofacial features in addition to
megalencephaly and multifocal seizures. Puffenberger et al [42]
reported 16 patients of whom 4 (38%) died during childhood due
to status epilepticus, congestive heart failure, and hypernatremic
dehydratation. A pathologic examination carried out in a single
patient disclosed the presence of megalencephaly, ventriculome-
galy, cytomegaly, and extensive vacuolization and astrocytosis in
the white matter.
Greig cephalo-polysyndactyly syndrome (GCPS) is linked to a
mutation involving the GLI3 protein, which is a zinc ﬁnger
transcription factor that is expressive in early development.
Patients present with preaxial or postaxial polydactily with or
without syndactily and craniofacial features, including large head
and hypertelorism. Abnormalities located in the corpus callosum
have been reported.[47] Démurger et al [48] state that macro-
cephaly was found in 32 of 53 (60%) patients with GCPS, but in
7 of 18 patients (39%), a severe ventricular dilatation was
present.
Acrocallosal syndrome is an autosomal recessive disorder that
manifests with corpus callosum agenesis, facial dysmorphism,
postaxial polydactily of the hands as well as preaxial polydactyly
of the feet. The disorder is linked to a mutation of the KIF7 gene
that encodes a molecule within the sonic hedgehog.[49] The
reported large head has been related to enlarged ventricles [50]
and therefore should not be included in the group of
megalencephaly as with the GCPS.
In Opitz–Kaveggia syndrome, also known as “FG syndrome,”
the mutation involves the MED12 gene, which is located on
Xq13 and is a member of the large mediator complex; it has a
relevant role in RNA polymerase II transcription. The mutations
ofMED12 can cause, in addition to the FG syndrome, the Lujan
syndrome and Ohdo syndrome.[51,52] Affected male patients
present distinctive facial appearance, mental retardation, large
[8] Ono Y, Saito Y, Maegaki Y, et al. Three cases of right frontal
Pavone et al. Medicine (2017) 96:26 Medicinehead, imperforate anus, and hypotonia. In the classical report of
Opitz and Kaveggia,[53] the syndrome was designed as a multiple
congenital anomaly syndrome with signs of relative macro-
cephaly, broad and ﬂat thumbs, emperforate anus, hypotonia,
and moderately severe cognitive delay.
Nguyen et al [54] reported a new autosomal-recessive
neurological condition characterized by megalencephaly, thick
corpus callosum, and severe intellectual disability. The boy
presented with neonatal overgrowth of the occipital-frontal
circumference at the 90th percentile, +3 SDs at the age of 14 years
and 66.5cm at 18 years of age. Facial features included a long
face with high forehead, prognatism, and long and thin feet and
hands. Severe myopia, thick corpus callosum, enlarged white
matter, and small cerebellum were also reported. The syndrome
seems to be caused by a homozygous nonsense variant in the
HERC1 protein that is an ubiquitin ligase that interacts with
tuberous sclerosis complex 2, an upstream negative regulator of
the mTOR pathway.
Grotto et al [55] reported 5 patients affected by severe
intellectual disability linked to BRWD3 nonsense mutation, p.
Tyr131, and compared the clinical presentations to those of 4
patients previously reported. The main symptoms consisted of
intellectual disability that ranged frommild tomoderate (9/9) and
speech delay (8/9); also, a large head was present in 7 of 9
patients. Among these, one patient presented with neonatal
overgrowth and large head; at the age of 12 years, the weight,
length, and head circumference measurements were +3.5 to 4.5
SDs. In this group of patients, dysmorphic features were also
present, including high forehead, hypertelorism, short palpebral
ﬁssures, anteverted nares, pointed chin, broad hands and feet,
joint laxity, genu valgum, and small penis.
Developmental delay labeled macrocephaly syndrome in a
large Amish kindred with an autosomal recessive inheritance was
described and related to homozygous or compound heterozygous
mutations in the KPTN gene encoding kaptin.[56]6. Conclusions
Megalencephaly is a congenital condition characterized by severe
overdeveloped brain size. Several congenital conditions and
several molecular mutations may cause megalencephaly, and in
most of the cases they are associated with other cerebral and
clinical anomalies. The condition has to be distinguished by the
macrocephaly that presents with different clinical situations.
Among the different gene mutations that cause cerebral
overgrowth, particular attention should be given to those
involving RTK/P13K/mTOR and MAPK/ERT and SHH
pathways.[38–40]References
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